22157.jpg
Global Blood Glucose Test Strips Market Report 2022: Steady Shift of Blood Sugar Tests from Diagnostic Laboratories and Hospitals to Easy-To-Use Test Kits Driving Sector
September 22, 2022 05:53 ET | Research and Markets
Dublin, Sept. 22, 2022 (GLOBE NEWSWIRE) -- The "Blood Glucose Test Strips Market By Distribution Type, By Diabetes Type, By End-use, and By Region Forecast to 2030" report has been added to ...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
September 07, 2022 02:00 ET | Zealand Pharma
Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association
June 14, 2020 11:00 ET | Zealand Pharma
Press release – No. 09 / 2020   Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association...
Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg
Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia
March 31, 2020 09:45 ET | Zealand Pharma
Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia The...
Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development
March 08, 2018 18:00 ET | Xeris Pharmaceuticals, Inc.
CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) -- CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...
xeris_logo-1.png
Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
February 15, 2018 17:00 ET | Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
xeris_logo-1.png
FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.
February 08, 2018 18:30 ET | Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
XOMA-Logo-Final.png
XOMA Reports Third Quarter 2016 Achievements and Financial Results
November 09, 2016 09:00 ET | XOMA Ltd.
BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...
Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia
November 03, 2016 11:00 ET | The Centre for Drug Research and Development
VANCOUVER, BC and TORONTO, ON--(Marketwired - November 03, 2016) - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent...
XOMA-Logo-Final.png
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
October 19, 2016 09:00 ET | XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...